186 results
8-K
EX-99.2
VANI
Vivani Medical Inc
13 May 24
Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results
4:57pm
at Nektar Therapeutics (responsible for Exubera approval), and Worldwide VP at Johnson & Johnson Truc Le, MBA –Chief Operations Officer Former Chief … by FDA to identify NDA deficiencies 21
(Intarcia) FDA alleges that daily variations in drug release may be responsible for clinical safety signals
8-K
EX-99.2
rppx3
26 Mar 24
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
8:31am
8-K
EX-4.1
hs61536zl4uxx68zvv
5 Mar 24
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
4:21pm
8-K
EX-10.1
v3s1lva 2uiq
5 Mar 24
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
4:21pm
424B5
x2gnmxjd48g va
5 Mar 24
Prospectus supplement for primary offering
11:31am
8-K
EX-99.2
h1cseq
28 Feb 24
Regulation FD Disclosure
8:30am
8-K
EX-99.1
er6wec
14 Nov 23
Results of Operations and Financial Condition
6:06am
8-K
EX-99.1
3inizh aa9ybacmwxht5
18 Sep 23
Regulation FD Disclosure
6:20am